Drug Combo Proves Powerful Against Lung Cancer Latham NY

A two-drug combination treatment in Latham proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

George Dubar Wilner
(518) 262-5454
47 New Scotland Ave
Albany, NY
Rufus Collea
(518) 262-6696
43 New Scotland Ave
Albany, NY
JOHN RICHARDS, MD
(518) 382-7200
530 Liberty Street
Schenectady, NY
Arthur Lewis Sunkin, MD
518-271-3220
3 S Colonial Hts
Troy, NY
Charles Henry Weissman, MD
518-786-3122
PO Box 610
Latham, NY
Ankesh Nigam
(518) 262-5623
47 New Scotland Ave
Albany, NY
John Jaski
(518) 399-4600
896 Riverview Rd
Rexford, NY
MICHAEL KOLODZIEJ, MD
(518) 489-0044
400 Patroon Creek Boulevard
Albany, NY
JANET GARGIULO, MD
(518) 786-3122
1003 Louden
Cohoes, NY
Muhammad Siddique Tai, MD
518-399-4600
896 Riverview Rd
Rexford, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Latham NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Fungal Infection Treatments Latham NY
- Genetic Clues for Skin Cancer Therapies Latham NY
- Exercise for Prostate Cancer Latham NY
- Side Effect Of Chemotherapy Drugs Latham NY
- Risks for Childhood Cancer Survivors Latham NY
- Hormone Therapy for Breast Cancer Latham NY
- Delayed Prostate Cancer Therapy Latham NY
- Exercise for Breast Cancer Survival Latham NY